---
title: Link gut microbiome to tremor
nct_id: NCT06848192
status: RECRUITING
sponsor: Westlake University
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06848192"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06848192"
last_fetched: "2026-05-10T14:06:48.816Z"
source: "Parkinson's Pathways (curated)"
---
# Link gut microbiome to tremor

**Goal (in five words):** Link gut microbiome to tremor

**Official Title:** The Parkinson's Disease Case-Control Study: Gut Microbiome Study for Parkinson's Disease

**Trial ID:** [NCT06848192](https://clinicaltrials.gov/study/NCT06848192)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Westlake University
- **Target Enrollment:** 40 participants
- **Start Date:** 2025-03-05
- **Completion Date:** 2025-12
- **Conditions:** Parkinson Disease

## Summary For Families

They want to find specific differences in the gut microbiome that are linked to Parkinson's, which could help explain disease mechanisms or point to future biomarkers or therapies. To do that, researchers will collect and compare gut microbiome samples and clinical data from people with Parkinson's and closely matched healthy volunteers, carefully excluding factors that alter gut bacteria such as recent antibiotic use, inflammatory gut disease, chronic constipation, and certain chronic illnesses. The study is looking for adults 50 to 75 years old with a clinical Parkinson's diagnosis and typical motor signs, plus age- and sex-matched healthy controls with no first-degree relatives with Parkinson's, and everyone must be able to give informed consent.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

(For PD patients)

1. Men or women aged 50 to 75 years.
2. Clinical diagnosis of Parkinson's disease (based on MDS Parkinson's disease diagnostic criteria)
3. The patient must have at least two of the following symptoms: static tremor, bradykinesia, stiffness (which must include at least static tremor or bradykinesia); Or have asymmetrical resting tremors or asymmetrical bradykinesia.
4. Able to provide informed consent.

(For healthy volunteers)

1. Age (±2 years) and sex-matched healthy control individuals for each Parkinson's disease patient.
2. Able to provide informed consent.

Exclusion Criteria:

(For PD patients)

1. Atypical or secondary parkinsonism due to medications (e.g., metoclopramide, flunarizine, antipsychotics) or metabolic diseases (e.g., Wilson's disease), encephalitis, or degenerative diseases (e.g., progressive supranuclear palsy).
2. The presence of clinically diagnosed dementia as determined by the investigator.
3. Previous MRI scans showed clinically significant neurological disorders (as judged by the investigator).
4. Serious illness (e.g., heart failure or malignancy).
5. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction
6. Inflammatory gastrointestinal diseases.
7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).
8. Blood or autoimmune disease, or use of immunosuppressants in the past 3 months.
9. Antibiotics have been used within 3 months prior to sample collection.
10. Chronic constipation.

(For healthy volunteers)

1. Have a first-degree relative with Parkinson's disease (e.g. biological parent, sibling, or child).
2. Current or past clinically significant neurological disorders (as judged by the investigator).
3. Previous MRI scans showed clinically significant neurological disorders (as judged by the investigator).
4. Use of the following drugs in the 6 months prior to the screening visit: dopamine blockers (antipsychotics), metoclopramide, and riserpine.
5. Inflammatory gastrointestinal diseases.
6. Smoking more than 15 cigarettes a day and a history of alcohol or drug addiction
7. Chronic diseases that may affect the gut microorganism (e.g., diabetes, cirrhosis, or cardiovascular disease).
8. Blood or autoimmune disease, or use of immunosuppressants in the past 3 months.
9. Antibiotics have been used within 3 months prior to sample collection.
10. Chronic constipation.
11. Participating in other clinical trials
```

## Locations (1)

- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China _(30.2936, 120.1614)_
  - Ju-Sheng Zheng, PhD — (CONTACT) — 86-0571-86915303 — zhengjusheng@westlake.edu.cn
  - Ju-sheng Zheng, PhD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Ju-Sheng Zheng, PhD — (CONTACT) — 86-0571-86915303 — zhengjusheng@westlake.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT06848192*  
*HTML version: https://parkinsonspathways.com/trial/NCT06848192*  
*Source data: https://clinicaltrials.gov/study/NCT06848192*